Shanghai, September 29, 2022 – Congratulations to NanoRay Biotech Co., Ltd.’s [Auger Molecular Therapy], which has been approved by the US FDA for Clinical Trial. “Auger Molecular Therapy” (AMT) is a novel compound cancer treatment method that delivers iodine-containing iodine by intratumoral injection. After the tumor has been irradiated with the drug IUdR, the cancer cells are destroyed by the Auger Effect caused by the single-energy light.

BioDuro-Sundia assists NanoRay Biotech in the development of new dosage forms, API production, as well as the production of clinical trial materials (CTM), which has accelerated NanoRay’s research and development process. It is our hope that NanoRay will succeed in bringing more innovative therapies to patients throughout the world.

NanoRay Biotech has developed X-Ray source technology that has been applied to three fields: industrial inspection, medical imaging, and cancer treatment. In contrast to the continuum spectrum produced by traditional reflection X-rays, NanoRay’s exclusive patented penetrating X-ray tubes produce single-energy light concentrated in a specific energy spectrum section. A monoenergetic light is applied to this Auger molecular therapy at 33KeV, an energy equivalent to the iodine atom’s K-layer electron orbital binding energy. Consequently, when the 33KeV monoenergetic light hits the IUdR nearby the cancer cell’s DNA, a large number of Auger electrons are generated through the iodine atom, damaging the adjacent DNA and killing the cancer cell.

About BioDuro-Sundia

BioDuro-Sundia, an Advent International portfolio company is a trusted, leading Contract Research, Development and Manufacturing Organization (CRDMO) for over 27 years. We provide our biotech and pharmaceutical partners with fully integrated services to support their efforts from target identification through to commercial drug product manufacturing. The company is based in the US and China with more than 2,500 employees and 10 global sites across 7 cities.

Core expertise includes small and large molecule discovery, development and scale up, support for IND submission, and unique technology platforms such as bioavailability enhancement of insoluble compounds. The one-stop-shop operation helps biotech and pharma partners across the globe to significantly accelerate discovery and de-risk development to create higher value outcomes. We adhere to one global highest standard of compliance and business operation code. Science-driven, customer-oriented, flexible, people focused culture enables us to provide top-tier integrated, fast and flexible tailored services to our customers to meet their unique needs and accelerate development timeline.

We use necessary cookies to ensure our website functions properly and to keep it secure. These necessary cookies must be enabled. By clicking “Accept All Cookies”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. You can personalize or withdraw your consent at any moment by clicking on the link "Cookies Settings". For more information on how we use cookies, including the total lifespan of cookies and the identity of third parties intervening on our website, please consult the Privacy Notice available in the site footer.
Accept all